Kirkpatrick succeeds current CEO Gary Munsinger, Ph.D., who is also chairman of the RCT board of directors.
The Tucson, AZ-based company has played an early role in the commercial success of the anticancer drugs cisplatin and carboplatin, the prostate-specific antigen (PSA) blood test for prostate cancer, and technetium-99-based imaging agents.
By AuntMinnie.com staff writers
May 26, 2005
Copyright © 2005 AuntMinnie.com